Silo Pharma reports promising SPC-15 study for PTSD therapy
- ByInvesting.com
- •
Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. The company’s lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. It also develops SPC-14, which is in preclinical trial to treat Alzheimer’s disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. In addition, the company seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, PTSD, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.